Search

Your search keyword '"Kelley, Robin Kate"' showing total 259 results
Start Over Author "Kelley, Robin Kate"
259 results on '"Kelley, Robin Kate"'

1. Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma.

Author

Spencer, Kristen, Pappas, Leontios, Baiev, Islam, Maurer, Jordan, Bocobo, Andrea Grace, Zhang, Karen, Jain, Apurva, De Armas, Anaemy Danner, Reyes, Stephanie, Le, Tri Minh, Rahma, Osama E, Stanton, Jennifer, DeLeon, Thomas T, Roth, Marc, Peters, Mary Linton B, Zhu, Andrew X, Lennerz, Jochen K, Iafrate, A John, Boyhen, Kylie, VanCott, Christine, Roberts, Lewis R, Lindsey, Stacie, Horick, Nora, Goff, Laura Williams, Mody, Kabir, Borad, Mitesh J, Shroff, Rachna T, Kelley, Robin Kate, Javle, Milind M, and Goyal, Lipika

Subjects
Bile Ducts, Intrahepatic, Humans, Cholangiocarcinoma, Bile Duct Neoplasms, Prognosis, Risk Factors, Retrospective Studies, Patient Safety, Liver Cancer, Digestive Diseases - (Gallbladder), Rare Diseases, Liver Disease, Clinical Trials and Supportive Activities, Cancer, Clinical Research, Digestive Diseases, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundTreatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) differ, but limited studies exist comparing them. This study examines differences in molecular profiling rates and treatment patterns in these populations, focusing on use of adjuvant, liver-directed, targeted, and investigational therapies.MethodsThis multicenter collaboration included patients with ICC or ECC treated at 1 of 8 participating institutions. Retrospective data were collected on risk factors, pathology, treatments, and survival. Comparative statistical tests were 2-sided.ResultsAmong 1039 patients screened, 847 patients met eligibility (ICC = 611, ECC = 236). Patients with ECC were more likely than those with ICC to present with early stage disease (53.8% vs 28.0%), undergo surgical resection (55.1% vs 29.8%), and receive adjuvant chemoradiation (36.5% vs 4.2%) (all P

Published
2023

3. Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Author

Song, Xuyang, Kelley, Robin Kate, Khan, Anis A, Standifer, Nathan, Zhou, Diansong, Lim, KyoungSoo, Krishna, Rajesh, Liu, Lu, Wang, Kun, McCoon, Patricia, Negro, Alejandra, He, Philip, Gibbs, Megan, Kurland, John F, and Abou-Alfa, Ghassan K

Subjects
Rare Diseases, Clinical Research, Cancer, Humans, Carcinoma, Hepatocellular, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Liver Neoplasms, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeA novel single-dose regimen of 300 mg tremelimumab in combination with durvalumab [Single Tremelimumab Regular Interval Durvalumab (STRIDE)] has demonstrated a favorable benefit-risk profile in the phase I/II Study 22 (NCT02519348) and phase III HIMALAYA study (NCT03298451). This study evaluated the pharmacokinetics, exposure-response, and exposure-pharmacodynamics relationships of tremelimumab in patients with unresectable hepatocellular carcinoma (uHCC).Patients and methodsA previous tremelimumab population pharmacokinetic model was validated using data from parts 2 and 3 of Study 22. Exposure-response analyses explored relationships of tremelimumab exposure with efficacy and safety. Pharmacokinetics and pharmacodynamics relationships were evaluated using linear and nonlinear regression models.ResultsThe observed pharmacokinetics of tremelimumab in uHCC were consistent with predictions; no significant covariates were identified. Tremelimumab exposure was not significantly associated with adverse events, objective response rate, or progression-free survival. Overall survival (OS) was longer for patients with tremelimumab exposure, minimum serum drug concentration (Cmin1) ≥ median versus Cmin1 < median (18.99 months vs. 10.97 months), but this exposure-survival analysis might be confounded with baseline characteristics of albumin level and neutrophil to lymphocyte ratio, which had a significant impact on OS (P = 0.0004 and 0.0001, respectively). The predicted Cmin1 of tremelimumab in STRIDE regimen (12.9 μg/mL) was greater than the estimated concentration of tremelimumab eliciting half-maximal increases (EC50 = 5.24 μg/mL) in CD8+Ki67+ T-cell counts.ConclusionsOur findings support novel insights into tremelimumab pharmacokinetics and exposure-response relationships in HCC and support the clinical utility of the STRIDE regimen in patients with uHCC.

Published
2023

4. Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab + bevacizumab treatment of hepatocellular carcinomaAFP as a surrogate biomarker for atezo + bev therapy in HCC

Author

Zhu, Andrew X, Dayyani, Farshid, Yen, Chia-Jui, Ren, Zhenggang, Bai, Yuxian, Meng, Zhiqiang, Pan, Hongming, Dillon, Paul, Mhatre, Shivani K, Gaillard, Vincent E, Hernandez, Sairy, Kelley, Robin Kate, and Sangro, Bruno

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Hepatitis, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Liver Cancer, Digestive Diseases, Liver Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Antibodies, Monoclonal, Humanized, Bevacizumab, Biomarkers, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Retrospective Studies, alpha-Fetoproteins, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeAtezolizumab + bevacizumab is the new standard of care for systemic treatment-naïve, unresectable hepatocellular carcinoma (HCC). This exploratory study investigated on-treatment alpha-fetoprotein (AFP) response as a potential surrogate biomarker of prognosis for the combination therapy.Experimental designData from Group A of the phase Ib GO30140 study were used to identify the optimal time for AFP measurement and AFP cutoffs to differentiate patients by their best confirmed response per independent review facility-assessed RECIST (IRF-RECIST) version 1.1: responders from nonresponders and patients with disease control from primary progressors. We applied these cutoffs to independent data from the atezolizumab + bevacizumab arm of the phase III IMbrave150 trial to distinguish patients based on (i) overall survival (OS) and progression-free survival (PFS) per IRF-RECIST 1.1 and (ii) best confirmed response per IRF-RECIST 1.1.ResultsWe derived AFP cutoffs of ≥75% decrease and ≤10% increase from baseline at 6 weeks to identify responders and those who had disease control, respectively. These cutoffs had high sensitivity and specificity in GO30140. In IMbrave150 patients, sensitivity was 0.59 and specificity was 0.86 for the ≥75% decrease AFP cutoff; the sensitivity was 0.77 and specificity was 0.44 for the ≤10% increase AFP cutoff. Both AFP cutoffs were associated with longer OS and PFS, particularly in patients with hepatitis B virus etiology (HR < 0.5; P < 0.01).ConclusionsAFP response at 6 weeks after initiating treatment is a potential surrogate biomarker of prognosis for patients with HCC receiving atezolizumab + bevacizumab. See related commentary by Cappuyns and Llovet, p. 3405.

Published
2022

5. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Author

Azevedo, Sergio, Braghiroli, Maria Ignez, Girotto, Gustavo, Bragagnoli, Arinilda, Branco, Ricardo, Faccio, Adilson, Moretto, Andrea, Skare, Nils, Dutra, Jamille, Viola, Luciana, Vianna, Karina, Meton, Fernando, Sette, Claudia, Faulhaber, Amanda, Tam, Vincent C., Couture, Felix, Biagi, Jim, Castel, Helene, Mulder, Karen, Ko, Yoo-Joung, Zbuk, Kevin, Welch, Stephen, Beaudoin, Annie, Heurgué, Alexandra, Assenat, Eric, Archambeaud, Isabelle, Tougeron, David, Peron, Jean-Marie, Gilabert, Marine, Bronowicki, Jean-Pierre, Cattan, Stephane, Blanc, Jean-Frederic, Bouattour, Mohamed, Phelip, Jean-Marc, Boige, Valerie, Michel, Pierre, Frin, Anne-Claire, De Toni, Enrico N., Berres, Marie-Luise, Vogel, Arndt, Berg, Thomas, Ettrich, Thomas, Waldschmidt, Dirk, Wedemeyer, Hans Heinrich, Worns, Marcus-Alexander, Bitzer, Michael, Weiss, Karl-Heinz, Lau, George, Chan, Stephen L., Yau, Thomas, Tai, Yin Ping, Lee, Ann Shing, Thungappa, Satheesh Chiradoni, N, Lokesh K., Sureshchand Ostwal, Vikas, Ashok, Kattimani Kiran, Mittal, Sushant, Goyal, Hari, Srinivasan, Sankar, Biswas, Ghanashyam, Mohan, Mallavarapu, Limaye, Sewanti, Asarawala, Nirav, Rimassa, Lorenza, Falcone, Alfredo, Gianni, Luca, Gasbarrini, Antonio, Daniele, Bruno, Avallone, Antonio, Paolo Frassineti, Giovanni Luca, Roila, Fausto, Kudo, Masatoshi, Kawaoka, Tomokazu, Morimoto, Manabu, Takikawa, Yasuhiro, Kato, Naoya, Yamashita, Tatsuya, Osaki, Yukio, Motomura, Kenta, Tateishi, Ryosuke, Ohkawa, Kazuyoshi, Wada, Yoshiyuki, Onishi, Hideki, Sasahira, Naoki, Inaba, Yoshitaka, Kurosaki, Masayuki, Tsuji, Kunihiko, Takei, Yoshiyuki, Aramaki, Takeshi, Hagihara, Atsushi, Furuse, Junji, Kioka, Kiyohide, Koga, Hironori, Sasaki, Yutaka, Numata, Kazushi, Tada, Toshifumi, Kawaguchi, Yasunori, Nadano, Seijin, Vasilyev, Alexander, Breder, Valery, Lipatov, Oleg, Dvorkin, Mikhail, Zarubenkov, Oleg, Kutukova, Svetlana, Ponomarev, Roman, Shostka, Kirill, Alyasova, Anna, Topuzov, Eldar, Severtsev, Alexey, Petrov, Yuryi, Erygin, Dmitriy, Berdov, Boris, Kang, Yoon-Koo, Tak, Won-Young, Park, Joong-Won, Lim, Ho Yeong, Heo, Jeong, Kim, Jee Hyun, Kim, Tae-You, Choi, Hye Jin, Varela, María, Reig Monzon, María Elisa, Sangro, Bruno, Martin, Carlos Gómez, Ponce, Carmen Guillén, López, Carlos, Cheng, Ann-Lii, Chao, Yee, Feng, Yin-Hsun, Jeng, Long-Bin, Hung, Chao-Hung, Hou, Ming-Mo, Wang Tsang-En Wang, Jing-Houng, Yen, Chia-Jui, Sukeepaisarnjaroen, Wattana, Sunpaweravong, Patrapim, Charoentum, Chaiyut, Tanasanvimon, Suebpong, Sirachainan, Ekaphop, Ungtrakul, Teerapat, Prasongsook, Naiyarat, Maneenil, Kunlatida, Jitpewngarm, Wittawat, Ostapenko, Yurii, Skoryi, Denys, Bondarenko, Igor, Shparyk, Yaroslav, Trukhin, Dmytro, Hotko, Yevhen, Ursol, Grygorii, Kryzhanivska, Anna, Abou-Alfa, Ghassan K., Mody, Kabir, Dayyani, Farshid, Al-Rajabi, Raed, Yarchoan, Mark, Gandhi, Sunil, Crysler, Oxana, He, Aiwu Ruth, Reeves, James, Bahary, Nathan, Mahipal, Amit, Kelley, Robin Kate, Dasgupta, Anirudha, Rowe, Julie, Thota, Ramya, Beg, Muhammad, Morse, Michael, Choi, Sung-hee, Crocenzi, Todd, Somer, Bradley, Abrams, Thomas, Denlinger, Crystal, Zhang, Yue, Sharma, Nisha, Dao, Tu V., Thinh, Nguyen Tien, Tuyet Phuong, Le Thi, Sangro, B., Chan, S.L., Kelley, R.K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E.N., Furuse, J., Kang, Y.K., Galle, P.R., Rimassa, L., Heurgué, A., Tam, V.C., Van Dao, T., Thungappa, S.C., Breder, V., Ostapenko, Y., Reig, M., Makowsky, M., Paskow, M.J., Gupta, C., Kurland, J.F., Negro, A., and Abou-Alfa, G.K.

Published
2024
Full Text
View/download PDF

6. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

Author

Yau, Thomas, Kaseb, Ahmed, Cheng, Ann-Lii, Qin, Shukui, Zhu, Andrew X, Chan, Stephen L, Melkadze, Tamar, Sukeepaisarnjaroen, Wattana, Breder, Valery, Verset, Gontran, Gane, Edward, Borbath, Ivan, Rangel, Jose David Gomez, Ryoo, Baek-Yeol, Makharadze, Tamta, Merle, Philippe, Benzaghou, Fawzi, Milwee, Steven, Wang, Zhong, Curran, Dominic, Kelley, Robin Kate, and Rimassa, Lorenza

Published
2024
Full Text
View/download PDF

7. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade

Author

Kelley, Robin Kate, Miksad, Rebecca, Cicin, Irfan, Chen, YenHsun, Klümpen, Heinz-Josef, Kim, Stefano, Lin, Zhong-Zhe, Youkstetter, Jillian, Hazra, Saswati, Sen, Suvajit, Cheng, Ann-Lii, El-Khoueiry, Anthony B, Meyer, Tim, and Abou-Alfa, Ghassan K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, Digestive Diseases, Liver Cancer, Clinical Trials and Supportive Activities, Liver Disease, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Administration, Oral, Adult, Aged, Aged, 80 and over, Anilides, Bilirubin, Carcinoma, Hepatocellular, Female, Humans, Liver Function Tests, Liver Neoplasms, Male, Middle Aged, Pyridines, Retrospective Studies, Serum Albumin, Survival Analysis, Treatment Outcome, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundAlbumin-bilirubin (ALBI) grade is an objective measure of liver function for patients with hepatocellular carcinoma (HCC). The tyrosine kinase inhibitor cabozantinib is approved for patients with advanced HCC who have received prior sorafenib based on the phase 3 CELESTIAL trial (NCT01908426). Cabozantinib improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated HCC.MethodsPatients were randomised 2:1 to receive cabozantinib 60 mg or placebo orally every day. Clinical outcomes in patients with ALBI grade 1 or 2 at baseline were evaluated in CELESTIAL. ALBI scores were retrospectively calculated based on baseline serum albumin and total bilirubin, with an ALBI grade of 1 defined as  ≤ -2.60 score and a grade of 2 as a score of > -2.60 to  ≤ -1.39.ResultsCabozantinib improved OS and PFS versus placebo in both ALBI grade 1 (hazard ratio [HR] [95% CI]: 0.63 [0.46-0.86] and 0.42 [0.32-0.56]) and ALBI grade 2 (HR [95% CI]: 0.84 [0.66-1.06] and 0.46 [0.37-0.58]) subgroups. Adverse events were consistent with those in the overall population. Rates of grade 3/4 adverse events associated with hepatic decompensation were generally low and were more common among patients in the ALBI grade 2 subgroup.DiscussionThese results provide initial support of cabozantinib in patients with advanced HCC irrespective of ALBI grade 1 or 2.Trial registration numberClinicalTrials.gov number, NCT01908426.

Published
2022

8. Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

Author

Meric-Bernstam, Funda, Bahleda, Rastislav, Hierro, Cinta, Sanson, Marc, Bridgewater, John, Arkenau, Hendrik-Tobias, Tran, Ben, Kelley, Robin Kate, Park, Joon Oh, Javle, Milind, He, Yaohua, Benhadji, Karim A, and Goyal, Lipika

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Cancer, Breast Cancer, Prevention, Clinical Research, Digestive Diseases, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antineoplastic Agents, Bile Duct Neoplasms, Cholangiocarcinoma, Disease-Free Survival, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Pyrazoles, Pyrimidines, Pyrroles, Receptor, Fibroblast Growth Factor, Type 1, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Futibatinib, a highly selective, irreversible FGFR1-4 inhibitor, was evaluated in a large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors. Futibatinib demonstrated an objective response rate (ORR) of 13.7%, with responses in a broad spectrum of tumors (cholangiocarcinoma and gastric, urothelial, central nervous system, head and neck, and breast cancer) bearing both known and previously uncharacterized FGFR1-3 aberrations. The greatest activity was observed in FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma (ORR, 25.4%). Some patients with acquired resistance to a prior FGFR inhibitor also experienced responses with futibatinib. Futibatinib demonstrated a manageable safety profile. The most common treatment-emergent adverse events were hyperphosphatemia (81.2%), diarrhea (33.5%), and nausea (30.4%). These results formed the basis for ongoing futibatinib phase II/III trials and demonstrate the potential of genomically selected early-phase trials to help identify molecular subsets likely to benefit from targeted therapy. SIGNIFICANCE: This phase I dose-expansion trial demonstrated clinical activity and tolerability of the irreversible FGFR1-4 inhibitor futibatinib across a broad spectrum of FGFR-aberrant tumors. These results formed the rationale for ongoing phase II/III futibatinib trials in cholangiocarcinoma, breast cancer, gastroesophageal cancer, and a genomically selected disease-agnostic population.This article is highlighted in the In This Issue feature, p. 275.

Published
2022

9. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Author

Kelley, Robin Kate, Sangro, Bruno, Harris, William, Ikeda, Masafumi, Okusaka, Takuji, Kang, Yoon-Koo, Qin, Shukui, Tai, David W-M, Lim, Ho Yeong, Yau, Thomas, Yong, Wei-Peng, Cheng, Ann-Lii, Gasbarrini, Antonio, Damian, Silvia, Bruix, Jordi, Borad, Mitesh, Bendell, Johanna, Kim, Tae-You, Standifer, Nathan, He, Philip, Makowsky, Mallory, Negro, Alejandra, Kudo, Masatoshi, and Abou-Alfa, Ghassan K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, HIV/AIDS, Orphan Drug, Rare Diseases, Cancer, Biotechnology, Clinical Research, Digestive Diseases, Clinical Trials and Supportive Activities, Liver Cancer, Patient Safety, Liver Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Carcinoma, Hepatocellular, Female, Humans, Liver Neoplasms, Male, Middle Aged, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThis phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose of tremelimumab (ClinicalTrials.gov identifier: NCT02519348).Patients and methodsPatients with HCC who had progressed on, were intolerant to, or refused sorafenib were randomly assigned to receive T300 + D (tremelimumab 300 mg plus durvalumab 1,500 mg [one dose each during the first cycle] followed by durvalumab 1,500 mg once every 4 weeks), durvalumab monotherapy (1,500 mg once every 4 weeks), tremelimumab monotherapy (750 mg once every 4 weeks [seven doses] and then once every 12 weeks), or T75 + D (tremelimumab 75 mg once every 4 weeks plus durvalumab 1,500 mg once every 4 weeks [four doses] followed by durvalumab 1,500 mg once every 4 weeks). Safety was the primary end point. Secondary end points included objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors v1.1 and overall survival; exploratory end points included circulating lymphocyte profiles.ResultsA total of 332 patients were enrolled (T300 + D, n = 75; durvalumab, n = 104; tremelimumab, n = 69; and T75 + D, n = 84). Tolerability was acceptable across arms, with grade ≥ 3 treatment-related adverse events occurring in 37.8%, 20.8%, 43.5%, and 24.4%, respectively. Confirmed ORRs (95% CI) were 24.0% (14.9 to 35.3), 10.6% (5.4 to 18.1), 7.2% (2.4 to 16.1), and 9.5% (4.2 to 17.9), respectively. An early expansion of CD8+ lymphocytes was associated with response across arms, with highest proliferating CD8+ lymphocyte levels occurring in the T300 + D arm. The median (95% CI) overall survival was 18.7 (10.8 to 27.3), 13.6 (8.7 to 17.6), 15.1 (11.3 to 20.5), and 11.3 (8.4 to 15.0) months in the T300 + D, durvalumab, tremelimumab, and T75 + D arms, respectively.ConclusionAll regimens were found to be tolerable and clinically active; however, the T300 + D regimen demonstrated the most encouraging benefit-risk profile. The unique pharmacodynamic activity and association with ORR of the T300 + D regimen further support its continued evaluation in HCC.

Published
2021

10. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

Author

Greten, Tim F, Abou-Alfa, Ghassan K, Cheng, Ann-Lii, Duffy, Austin G, El-Khoueiry, Anthony B, Finn, Richard S, Galle, Peter R, Goyal, Lipika, He, Aiwu Ruth, Kaseb, Ahmed O, Kelley, Robin Kate, Lencioni, Riccardo, Lujambio, Amaia, Hrones, Donna Mabry, Pinato, David J, Sangro, Bruno, Troisi, Roberto I, Woods, Andrea Wilson, Yau, Thomas, Zhu, Andrew X, and Melero, Ignacio

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Clinical Trials and Supportive Activities, Liver Cancer, Digestive Diseases, Rare Diseases, Vaccine Related, Cancer, Clinical Research, Liver Disease, Chronic Liver Disease and Cirrhosis, Patient Safety, Immunization, Good Health and Well Being, Carcinoma, Hepatocellular, Guidelines as Topic, Humans, Immunotherapy, Liver Neoplasms, antineoplastic protocols, immunotherapy, guidelines as topic, liver neoplasms, Oncology and carcinogenesis
Abstract

Patients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC has been transformed as a combination of the immune checkpoint inhibitor (ICI) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was shown to offer improved overall survival in the first-line setting. Immunotherapy has demonstrated safety and efficacy in later lines of therapy as well, and ongoing trials are investigating novel combinations of ICIs and TKIs, in addition to interventions earlier in the course of disease or in combination with liver-directed therapies. Because HCC usually develops against a background of cirrhosis, immunotherapy for liver tumors is complex and oncologists need to account for both immunological and hepatological considerations when developing a treatment plan for their patients. To provide guidance to the oncology community on important concerns for the immunotherapeutic care of HCC, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). The expert panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for HCC, including diagnosis and staging, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with HCC.

Published
2021

11. Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy

Author

Budhu, Anuradha, Pehrsson, Erica C., He, Aiwu, Goyal, Lipika, Kelley, Robin Kate, Dang, Hien, Xie, Changqing, Monge, Cecilia, Tandon, Mayank, Ma, Lichun, Revsine, Mahler, Kuhlman, Laura, Zhang, Karen, Baiev, Islam, Lamm, Ryan, Patel, Keyur, Kleiner, David E., Hewitt, Stephen M., Tran, Bao, Shetty, Jyoti, Wu, Xiaolin, Zhao, Yongmei, Shen, Tsai-Wei, Choudhari, Sulbha, Kriga, Yuliya, Ylaya, Kris, Warner, Andrew C., Edmondson, Elijah F., Forgues, Marshonna, Greten, Tim F., and Wang, Xin Wei

Published
2023
Full Text
View/download PDF

12. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Akce, Mehmet, Ales Diaz, Inmaculada, Alves, Gustavo, Anand, Sumitra, Arslan, Cagatay, Asselah, Jamil, Assenat, Eric, Aubin, Francine, Bai, Li-Yuan, Bai, Yuxian, Barajas, Olga, Bates, Susan, Begbie, Stephen, Ben-Aharon, Irit, Beri, Nina, Berres, Marie-Luise, Blanc, Jean-Frederic, Borbath, Ivan, Bordonaro, Robert, Bouattour, Mohamed, Brandi, Giovanni, Burgoyne, Adam, Butthongkomvong, Kritiya, Camandaroba, Marcos, Cao, Ke, Carballido, Marcela, Chan, Stephan Lam, Chen, Jen-Shi, Chen, Ming-Huang, Chen, Xiaoming, Cheng, Ashley, Chiu, Tai-Jan, Choi, Hye Jin, Chon, Hong Jae, Collignon, Joelle, Cubillo Gracian, Antonio, Davis, Sarah, de Carvalho, Ricardo Saraiva, de Groot, D.J.A., Demols, Anne, De Vos, Judith, Diab, Maria, Easaw, Jacob, Eatock, Martin, Edeline, Julien, Elias, Rawad, Eskens, Fredericus, Falcone, Alfredo, Fernandez, Plinio, Finn, Richard, Franke, Fabio, Furukawa, Masayuki, Furuse, Junji, Gbolahan, Olumide, Geboes, Karen, Geneser, Keri-Lee, Geng, Zhimin, Geva, Ravit, Gillmore, Roopinder, Goetze, Thorsten, Gou, Hongfeng, Grasselli, Julieta, Gu, Shanzhi, Gumus, Mahmut, Haj Mohammad, Nadia, Hao, Chunyi, Harputluoglu, Hakan, Hatoum, Hassan, Heinemann, Volker, Ho, Wang Kwong, Hsu, Chiun, Hubert, Ayala, Hwang, Juneul, Inanc, Mevlude, Iseas, Soledad, Jeyasingam, Vaishnavi, Jimenez Fonseca, Paula, Joubert, Warren, Juengsamarn, Jitlada, Kaen, Diego, Kanai, Masashi, Kasper-Virchow, Stefan, Kazemi, Ghazaleh, Kelleher, Fergal, Kelley, Robin, Kim, Jin Won, Kim, Jong Gwang, Kinupe Abrahao, Ana Beatriz, Klumpen, Heinz, Kochenderfer, Mark, Kose, Fatih, Lam, Ho Ching, Lee, Choong-kun, Lee, Hyun Woo, Lee, Margaret, Lee, Myung Ah, Lee, Wai Man Sarah, Le Sourd, Samuel, Li, Dongliang, Li, Wei, Liang, Houjie, Liang, Tingbo, Lim, Chun Sen, Lingerfelt, Brian, Lopez, Charles, Low, John, Macarulla Mercade, Teresa, Malka, David, Mao, Yimin, Masi, Gianluca, McCune, Steven, McDermott, Ray, McWhirter, Elaine, Mendez, Guillermo, Milella, Michele, Mizuno, Nobumasa, Mizutani, Tomonori, Moniz, Camila, Morales, Luisa, Munoz Martin, Andres Jesús, Nervi, Bruno, Ngamphaiboon, Nuttapong, Oh, Sang Cheul, Oksuzoglu, Berna, Outlaw, Darryl, Ozaka, Masato, Ozguroglu, Mustafa, Ozyilkan, Ozgur, Painemal, Claudio, Pan, Yueyin, Park, Joon Oh, Pelzer, Uwe, Peng, Chuang, Petorin, Caroline, Pezet, Denis, Power, Derek, Qin, Shukui, Ren, Zhenggang, Roohullah, Aflah, Ryu, Hyewon, Salman, Pamela, Sasaki, Mitsuhito, Sasidharan, Rita, Satoh, Taroh, Schulze, Kornelius, Scott-Brown, Martin, Segovia, Ruben, Seufferlein, Thomas, Siena, Salvatore, Sinapi, Isabelle, Smolenschi, Cristina, Song, Tianqiang, Sookprasert, Aumkhae, Soparattanapaisarn, Nopadol, Starling, Naureen, Stein, Stacey, Stemmer, Salomon, Su, Haichuan, Sugimoto, Rie, Suksombooncharoen, Thatthan, Tam, Vincent, Tan, Ai Lian, Tan, Chih Kiang, Tanasanvimon, Suebpong, Tonini, Giuseppe, Tortora, Giampaolo, Tsuji, Akihito, Ueno, Makoto, Uribe, Rodrigo, Venerito, Marino, Verdaguer Mata, Helena, Verslype, Chris, Victorino, Ana Paula, Vogel, Arndt, Wade, James, Waldschmidt, Dirk Thomas, Wang, Lu, Wan Isahk, Wan Zamaniah, Wasan, Harpeet, Weschenfelder, Rui, Wong, Chun Yin, Wong, Yoke Fui, Yalcin, Suayib, Yanez Weber, Patricio, Yang, Xuezhong, Yasui, Hisateru, Yau, Thomas, Yazici, Ozan, Yen, Chia-Jui, Ying, Jieer, Yoo, Changhoon, Yu, Wenchang, Zhao, Haitao, Kelley, Robin Kate, Finn, Richard S, Klümpen, Heinz-Josef, Chan, Stephen L, Valle, Juan W, Yu, Li, Malhotra, Usha, and Siegel, Abby B

Published
2023
Full Text
View/download PDF

13. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma

Author

Kelley, Robin Kate, Meyer, Tim, Rimassa, Lorenza, Merle, Philippe, Park, Joong-Won, Yau, Thomas, Chan, Stephen L, Blanc, Jean-Frederic, Tam, Vincent C, Tran, Albert, Dadduzio, Vincenzo, Markby, David W, Kaldate, Rajesh, Cheng, Ann-Lii, El-Khoueiry, Anthony B, and Abou-Alfa, Ghassan K

Subjects
Cancer, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Anilides, Carcinoma, Hepatocellular, Female, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Placebos, Prognosis, Progression-Free Survival, Protein Kinase Inhibitors, Pyridines, Reference Values, Young Adult, alpha-Fetoproteins, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe phase III CELESTIAL study demonstrated improved overall survival (OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with previously treated, advanced hepatocellular carcinoma (HCC). We analyzed outcomes by baseline alpha-fetoprotein (AFP) and on-treatment AFP changes.Patients and methodsSerum AFP was measured every 8 weeks by blinded, centralized testing. Outcomes were analyzed by baseline AFP bifurcated at 400 ng/mL and by on-treatment AFP response (≥20% decrease from baseline at Week 8). The optimal cutoff for change in AFP at Week 8 was evaluated using maximally selected rank statistics.ResultsMedian OS for cabozantinib versus placebo was 13.9 versus 10.3 months [HR, 0.81; 95% confidence interval (CI), 0.62-1.04] for patients with baseline AFP

Published
2020

14. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.

Author

Kelley, Robin Kate, Ryoo, Baek-Yeol, Merle, Philippe, Park, Joong-Won, Bolondi, Luigi, Chan, Stephen L, Lim, Ho Yeong, Baron, Ari D, Parnis, Francis, Knox, Jennifer, Cattan, Stéphane, Yau, Thomas, Lougheed, Julie C, Milwee, Steven, El-Khoueiry, Anthony B, Cheng, Ann-Lii, Meyer, Tim, and Abou-Alfa, Ghassan K

Subjects
Humans, Carcinoma, Hepatocellular, Liver Neoplasms, Anilides, Pyridines, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Adult, Aged, Aged, 80 and over, Middle Aged, Male, Young Adult, Sorafenib, cabozantinib, hepatocellular carcinoma, sorafenib, tyrosine kinase inhibitor, Clinical Research, Cancer, Clinical Trials and Supportive Activities, Digestive Diseases, Rare Diseases, Liver Cancer, Liver Disease, 6.1 Pharmaceuticals
Abstract

ObjectiveIn the phase 3 CELESTIAL trial, cabozantinib improved overall survival (OS) and progression-free survival (PFS) compared with placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). This subgroup analysis evaluated cabozantinib in patients who had received sorafenib as the only prior systemic therapy.MethodsCELESTIAL randomised (2:1) patients with advanced HCC and Child-Pugh class A liver function to treatment with cabozantinib (60 mg daily) or placebo. Eligibility required prior treatment with sorafenib, and patients could have received ≤2 prior systemic regimens. The primary endpoint was OS. Outcomes in patients who had received sorafenib as the only prior therapy were analysed by duration of prior sorafenib (

Published
2020

15. Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma

Author

Huppert, Laura A, Gordan, John D, and Kelley, Robin Kate

Subjects
Information and Computing Sciences, Biomedical and Clinical Sciences, Computer Vision and Multimedia Computation, Rare Diseases
Abstract

http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/15-2-reading-huppert a video presentation of this article Answer questions and earn https://www.wileyhealthlearning.com/Activity/7036144/disclaimerspopup.aspx.

Published
2020

16. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2

Author

Tsang, Erica S., primary, Dhawan, Mallika S., additional, Pacaud, Romain, additional, Thomas, Scott, additional, Grabowsky, Jennifer, additional, Wilch, Lauren, additional, Karipineni, Silpa, additional, Kelley, Robin Kate, additional, Ko, Andrew H., additional, Collisson, Eric, additional, Chapman, Jocelyn S., additional, Ueda, Stefanie, additional, Bergsland, Emily K., additional, and Munster, Pamela, additional

Published
2024
Full Text
View/download PDF

17. Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

Author

Sangro, Bruno, primary, Galle, Peter R., additional, Kelley, Robin Kate, additional, Charoentum, Chaiyut, additional, De Toni, Enrico N., additional, Ostapenko, Yurii, additional, Heo, Jeong, additional, Cheng, Ann-Lii, additional, Wilson Woods, Andrea, additional, Gupta, Charu, additional, Abraham, Jayne, additional, McCoy, Carrie L., additional, Patel, Nikunj, additional, Negro, Alejandra, additional, Vogel, Arndt, additional, and Abou-Alfa, Ghassan K., additional

Published
2024
Full Text
View/download PDF

18. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review

Author

Boscoe, Audra N, Rolland, Catherine, and Kelley, Robin Kate

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Brain Disorders, Clinical Research, Prevention, Digestive Diseases, Cancer, Cholangiocarcinoma, isocitrate dehydrogenase 1, prevalence, clinical prognosis, systematic review, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundThe recognition of distinct molecular subgroups within cholangiocarcinoma (CC), along with the increasing availability of targeted therapies, suggests that further characterization of the prevalence and prognosis of frequently occurring subgroups may assist with the development of more effective treatment approaches for the management of CC. A systematic review was performed to investigate the prevalence of isocitrate dehydrogenase 1 (IDH1) mutations (mIDH1) in patients with CC, the possible clinical and prognostic significance of mIDH1, and the presence of co-mutations in tumors with mIDH1.MethodsThis review was conducted using the Cochrane dual-reviewer methodology and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol (PRISMA-P) guidelines. Searches were performed in Embase, MEDLINE, the Cochrane Central Trials Register and Database of Systematic Reviews, and other Cochrane Library assets using terms for CC and mIDH1 with no language or date restrictions for articles published up to December 31, 2017. Searches were also performed of abstracts presented at the following conferences in 2016 and 2017: American Society of Clinical Oncology (ASCO), ASCO-Gastrointestinal Cancers Symposium (ASCO-GI), the European Society for Medical Oncology (ESMO), and ESMO-Asia. Screening was performed separately by two reviewers and cross-checked. Any discrepancies between reviewers were resolved by a senior researcher. Data from all selected references were recorded in a data extraction grid.ResultsA total of 46 publications met the inclusion criteria and were included in the systematic review. Of these publications, 45 reported the frequency of mIDH1 among a total sample of 5,393 patients with CC. mIDH1 was enriched in intrahepatic CC (ICC), with 552 (13.1%; 95% CI, 12.1-14.2) of the 4,214 patients with ICC having the mutation compared with 9 (0.8%; 95% CI, 0.4-1.5%) of the 1,123 patients with extrahepatic CC (ECC). The percentage of females with mIDH1 CC (66.2%; 95% CI, 57.7-73.7%) was higher than in the overall CC population (44.4%). The frequency of mIDH1 in patients with ICC reported in individual studies ranged from 4.5-55.6%, and a significantly higher frequency was reported in non-Asian centers compared with Asian centers (weighted mean, 16.5% vs. 8.8%; P

Published
2019

19. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Author

Kelley, Robin Kate, Rimassa, Lorenza, Cheng, Ann-Lii, Kaseb, Ahmed, Qin, Shukui, Zhu, Andrew X, Chan, Stephen L, Melkadze, Tamar, Sukeepaisarnjaroen, Wattana, Breder, Valery, Verset, Gontran, Gane, Edward, Borbath, Ivan, Rangel, Jose David Gomez, Ryoo, Baek-Yeol, Makharadze, Tamta, Merle, Philippe, Benzaghou, Fawzi, Banerjee, Kamalika, Hazra, Saswati, Fawcett, Jonathan, and Yau, Thomas

Published
2022
Full Text
View/download PDF

21. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Author

Yau, Thomas, Park, Joong-Won, Finn, Richard S, Cheng, Ann-Lii, Mathurin, Philippe, Edeline, Julien, Kudo, Masatoshi, Harding, James J, Merle, Philippe, Rosmorduc, Olivier, Wyrwicz, Lucjan, Schott, Eckart, Choo, Su Pin, Kelley, Robin Kate, Sieghart, Wolfgang, Assenat, Eric, Zaucha, Renata, Furuse, Junji, Abou-Alfa, Ghassan K, El-Khoueiry, Anthony B, Melero, Ignacio, Begic, Damir, Chen, Gong, Neely, Jaclyn, Wisniewski, Tami, Tschaika, Marina, and Sangro, Bruno

Published
2022
Full Text
View/download PDF

24. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

Author

Javle, Milind, Lowery, Maeve, Shroff, Rachna T, Weiss, Karl Heinz, Springfeld, Christoph, Borad, Mitesh J, Ramanathan, Ramesh K, Goyal, Lipika, Sadeghi, Saeed, Macarulla, Teresa, El-Khoueiry, Anthony, Kelley, Robin Kate, Borbath, Ivan, Choo, Su Pin, Oh, Do-Youn, Philip, Philip A, Chen, Li-Tzong, Reungwetwattana, Thanyanan, Van Cutsem, Eric, Yeh, Kun-Huei, Ciombor, Kristen, Finn, Richard S, Patel, Anuradha, Sen, Suman, Porter, Dale, Isaacs, Randi, Zhu, Andrew X, Abou-Alfa, Ghassan K, and Bekaii-Saab, Tanios

Subjects
Orphan Drug, Rare Diseases, Clinical Research, Digestive Diseases, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Administration, Oral, Adult, Aged, Antineoplastic Agents, Bile Duct Neoplasms, Biomarkers, Tumor, Cholangiocarcinoma, Disease Progression, Drug Administration Schedule, Gene Amplification, Gene Fusion, Genetic Predisposition to Disease, Humans, Middle Aged, Mutation, Phenotype, Phenylurea Compounds, Progression-Free Survival, Prospective Studies, Protein Kinase Inhibitors, Pyrimidines, Receptor, Fibroblast Growth Factor, Type 2, Time Factors, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose No standard treatment exists for patients with cholangiocarcinoma for whom first-line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective pan-FGFR kinase inhibitor, has shown preliminary clinical activity against tumors with FGFR alterations. Methods A multicenter, open-label, phase II study ( ClinicalTrials.gov identifier: NCT02150967) evaluated BGJ398 antitumor activity in patients age ≥ 18 years with advanced or metastatic cholangiocarcinoma containing FGFR2 fusions or other FGFR alterations whose disease had progressed while receiving prior therapy. Patients received BGJ398 125 mg once daily for 21 days, then 7 days off (28-day cycles). The primary end point was investigator-assessed overall response rate. Results Sixty-one patients (35 women; median age, 57 years) with FGFR2 fusion (n = 48), mutation (n = 8), or amplification (n = 3) participated. At the prespecified data cutoff (June 30, 2016), 50 patients had discontinued treatment. All responsive tumors contained FGFR2 fusions. The overall response rate was 14.8% (18.8% FGFR2 fusions only), disease control rate was 75.4% (83.3% FGFR2 fusions only), and estimated median progression-free survival was 5.8 months (95% CI, 4.3 to 7.6 months). Adverse events included hyperphosphatemia (72.1% all grade), fatigue (36.1%), stomatitis (29.5%), and alopecia (26.2%). Grade 3 or 4 treatment-related adverse events occurred in 25 patients (41%) and included hyperphosphatemia (16.4%), stomatitis (6.6%), and palmar-plantar erythrodysesthesia (4.9%). Conclusion BGJ398 is a first-in-class FGFR kinase inhibitor with manageable toxicities that shows meaningful clinical activity against chemotherapy-refractory cholangiocarcinoma containing FGFR2 fusions. This promising antitumor activity supports continued development of BGJ398 in this highly selected patient population.

Published
2018

25. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Author

Sangro, B., primary, Chan, S.L., additional, Kelley, R.K., additional, Lau, G., additional, Kudo, M., additional, Sukeepaisarnjaroen, W., additional, Yarchoan, M., additional, De Toni, E.N., additional, Furuse, J., additional, Kang, Y.K., additional, Galle, P.R., additional, Rimassa, L., additional, Heurgué, A., additional, Tam, V.C., additional, Van Dao, T., additional, Thungappa, S.C., additional, Breder, V., additional, Ostapenko, Y., additional, Reig, M., additional, Makowsky, M., additional, Paskow, M.J., additional, Gupta, C., additional, Kurland, J.F., additional, Negro, A., additional, Abou-Alfa, G.K., additional, Azevedo, Sergio, additional, Braghiroli, Maria Ignez, additional, Girotto, Gustavo, additional, Bragagnoli, Arinilda, additional, Branco, Ricardo, additional, Faccio, Adilson, additional, Moretto, Andrea, additional, Skare, Nils, additional, Dutra, Jamille, additional, Viola, Luciana, additional, Vianna, Karina, additional, Meton, Fernando, additional, Sette, Claudia, additional, Faulhaber, Amanda, additional, Tam, Vincent C., additional, Couture, Felix, additional, Biagi, Jim, additional, Castel, Helene, additional, Mulder, Karen, additional, Ko, Yoo-Joung, additional, Zbuk, Kevin, additional, Welch, Stephen, additional, Beaudoin, Annie, additional, Heurgué, Alexandra, additional, Assenat, Eric, additional, Archambeaud, Isabelle, additional, Tougeron, David, additional, Peron, Jean-Marie, additional, Gilabert, Marine, additional, Bronowicki, Jean-Pierre, additional, Cattan, Stephane, additional, Blanc, Jean-Frederic, additional, Bouattour, Mohamed, additional, Phelip, Jean-Marc, additional, Boige, Valerie, additional, Michel, Pierre, additional, Frin, Anne-Claire, additional, Enrico N De Toni, Germany, additional, Berres, Marie-Luise, additional, Vogel, Arndt, additional, Berg, Thomas, additional, Ettrich, Thomas, additional, Waldschmidt, Dirk, additional, Wedemeyer, Hans Heinrich, additional, Worns, Marcus-Alexander, additional, Bitzer, Michael, additional, Weiss, Karl-Heinz, additional, Lau, George, additional, Chan, Stephen L., additional, Yau, Thomas, additional, Tai, Yin Ping, additional, Lee, Ann Shing, additional, Thungappa, Satheesh Chiradoni, additional, N, Lokesh K., additional, Ostwal, Vikas Sureshchand, additional, Ashok, Kattimani Kiran, additional, Mittal, Sushant, additional, Goyal, Hari, additional, Srinivasan, Sankar, additional, Biswas, Ghanashyam, additional, Mohan, Mallavarapu, additional, Limaye, Sewanti, additional, Asarawala, Nirav, additional, Rimassa, Lorenza, additional, Falcone, Alfredo, additional, Gianni, Luca, additional, Gasbarrini, Antonio, additional, Daniele, Bruno, additional, Avallone, Antonio, additional, Paolo Frassineti, Giovanni Luca, additional, Roila, Fausto, additional, Kudo, Masatoshi, additional, Kawaoka, Tomokazu, additional, Morimoto, Manabu, additional, Takikawa, Yasuhiro, additional, Kato, Naoya, additional, Yamashita, Tatsuya, additional, Osaki, Yukio, additional, Motomura, Kenta, additional, Tateishi, Ryosuke, additional, Ohkawa, Kazuyoshi, additional, Wada, Yoshiyuki, additional, Onishi, Hideki, additional, Sasahira, Naoki, additional, Inaba, Yoshitaka, additional, Kurosaki, Masayuki, additional, Tsuji, Kunihiko, additional, Takei, Yoshiyuki, additional, Aramaki, Takeshi, additional, Hagihara, Atsushi, additional, Furuse, Junji, additional, Kioka, Kiyohide, additional, Koga, Hironori, additional, Sasaki, Yutaka, additional, Numata, Kazushi, additional, Tada, Toshifumi, additional, Kawaguchi, Yasunori, additional, Nadano, Seijin, additional, Alexander Vasilyev, Russian Federation, additional, Breder, Valery, additional, Lipatov, Oleg, additional, Dvorkin, Mikhail, additional, Zarubenkov, Oleg, additional, Kutukova, Svetlana, additional, Ponomarev, Roman, additional, Shostka, Kirill, additional, Alyasova, Anna, additional, Topuzov, Eldar, additional, Severtsev, Alexey, additional, Petrov, Yuryi, additional, Erygin, Dmitriy, additional, Berdov, Boris, additional, Kang, Yoon-Koo, additional, Tak, Won-Young, additional, Park, Joong-Won, additional, Lim, Ho Yeong, additional, Heo, Jeong, additional, Kim, Jee Hyun, additional, Kim, Tae-You, additional, Choi, Hye Jin, additional, Varela, María, additional, Reig Monzon, María Elisa, additional, Sangro, Bruno, additional, Martin, Carlos Gómez, additional, Ponce, Carmen Guillén, additional, López, Carlos, additional, Cheng, Ann-Lii, additional, Chao, Yee, additional, Feng, Yin-Hsun, additional, Jeng, Long-Bin, additional, Hung, Chao-Hung, additional, Hou, Ming-Mo, additional, Wang Tsang-En Wang, Jing-Houng, additional, Yen, Chia-Jui, additional, Sukeepaisarnjaroen, Wattana, additional, Sunpaweravong, Patrapim, additional, Charoentum, Chaiyut, additional, Tanasanvimon, Suebpong, additional, Sirachainan, Ekaphop, additional, Ungtrakul, Teerapat, additional, Prasongsook, Naiyarat, additional, Maneenil, Kunlatida, additional, Jitpewngarm, Wittawat, additional, Ostapenko, Yurii, additional, Skoryi, Denys, additional, Bondarenko, Igor, additional, Shparyk, Yaroslav, additional, Trukhin, Dmytro, additional, Hotko, Yevhen, additional, Ursol, Grygorii, additional, Kryzhanivska, Anna, additional, Abou-Alfa, Ghassan K., additional, Mody, Kabir, additional, Dayyani, Farshid, additional, Al-Rajabi, Raed, additional, Yarchoan, Mark, additional, Gandhi, Sunil, additional, Crysler, Oxana, additional, He, Aiwu Ruth, additional, Reeves, James, additional, Bahary, Nathan, additional, Mahipal, Amit, additional, Kelley, Robin Kate, additional, Dasgupta, Anirudha, additional, Rowe, Julie, additional, Thota, Ramya, additional, Beg, Muhammad, additional, Morse, Michael, additional, Choi, Sung-hee, additional, Crocenzi, Todd, additional, Somer, Bradley, additional, Abrams, Thomas, additional, Denlinger, Crystal, additional, Zhang, Yue, additional, Sharma, Nisha, additional, Dao, Tu V., additional, Thinh, Nguyen Tien, additional, and Tuyet Phuong, Le Thi, additional

Published
2024
Full Text
View/download PDF

26. Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study.

Author

Celsa, Ciro, primary, Nishida, Naoshi, additional, Arvind, Ashwini, additional, Ulahannan, Susanna Varkey, additional, Li, Michael, additional, Scheiner, Bernhard, additional, Fulgenzi, Claudia A.M., additional, D'Alessio, Antonio, additional, Manfredi, Giulia F, additional, Stefanini, Bernardo, additional, Cabibbo, Giuseppe, additional, Cortellini, Alessio, additional, Pinter, Matthias, additional, Kelley, Robin Kate, additional, El Tomb, Paul Antoine, additional, Singal, Amit G., additional, Kudo, Masatoshi, additional, and Pinato, David James, additional

Published
2024
Full Text
View/download PDF

27. Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.

Author

Rojas, Carlos, primary, Ryoo, Baek-Yeol, additional, Rha, Sun Young, additional, Kelley, Robin Kate, additional, Hubert, Ayala, additional, Painemal, Claudio, additional, Wadlow, Raymond Couric, additional, Gong, Jun, additional, Fan, Li, additional, Jin, Fan, additional, Naik, Girish S., additional, and Macarulla, Teresa, additional

Published
2024
Full Text
View/download PDF

28. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Author

Javle, Milind, Roychowdhury, Sameek, Kelley, Robin Kate, Sadeghi, Saeed, Macarulla, Teresa, Weiss, Karl Heinz, Waldschmidt, Dirk-Thomas, Goyal, Lipika, Borbath, Ivan, El-Khoueiry, Anthony, Borad, Mitesh J, Yong, Wei Peng, Philip, Philip A, Bitzer, Michael, Tanasanvimon, Surbpong, Li, Ai, Pande, Amit, Soifer, Harris S, Shepherd, Stacie Peacock, Moran, Susan, Zhu, Andrew X, Bekaii-Saab, Tanios S, and Abou-Alfa, Ghassan K

Published
2021
Full Text
View/download PDF

30. Hepatocellular carcinoma

Author

Llovet, Josep M., Kelley, Robin Kate, Villanueva, Augusto, Singal, Amit G., Pikarsky, Eli, Roayaie, Sasan, Lencioni, Riccardo, Koike, Kazuhiko, Zucman-Rossi, Jessica, and Finn, Richard S.

Published
2021
Full Text
View/download PDF

31. A phase i dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

Author

Munster, Pamela, Bergsland, Emily, Kelley, Robin Kate, Bendell, JC, Kelley, RK, Shih, KC, Grabowsky, JA, Jones, S, Martin, T, Infante, JR, Mischel, PS, and Matsutani, T

Abstract

© 2015 American Cancer Society.BACKGROUND The mammalian target of rapamycin (mTOR) pathway is essential for tumor development, yet mTOR inhibitors have yielded modest results. This phase 1 study investigated the mTORC1/mTORC2 inhibitor CC-223 in patients w

Published
2015

32. A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.

Author

Aranha, Olivia, Javle, Milind M., Rosales, Minori Koshiji, Hu, Zishuo Ian, Faridi, Amir A., Paulson, Scott, Richards, Donald A., Hochster, Howard S., Cosgrove, David, Azad, Nilofer Saba, Brown-Glaberman, Ursa, Cline, Vivian Jean M., Shumway, Nathan M., Tejani, Mohamedtaki Abdulaziz, Nallapareddy, Sujatha, Sahin, Ilyas, Borad, Mitesh J., Goyal, Lipika, and Kelley, Robin Kate

Published
2024
Full Text
View/download PDF

33. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

Author

Abou-Alfa, Ghassan K, primary, Lau, George, additional, Kudo, Masatoshi, additional, Chan, Stephen L, additional, Kelley, Robin Kate, additional, Furuse, Junji, additional, Sukeepaisarnjaroen, Wattana, additional, Kang, Yoon Koo, additional, Dao, Tu Van, additional, De Toni, Enrico N, additional, Rimassa, Lorenza, additional, Breder, Valeriy, additional, Vasilyev, Alexander, additional, Heurgué, Alexandra, additional, Tam, Vincent C, additional, Mody, Kabir, additional, Thungappa, Satheesh Chiradoni, additional, Ostapenko, Yurii, additional, Yau, Thomas, additional, Azevedo, Sergio, additional, Varela, María, additional, Cheng, Ann-Lii, additional, Qin, Shukui, additional, Galle, Peter R, additional, Ali, Sajid, additional, Gupta, Charu, additional, Makowsky, Mallory, additional, Kurland, John F, additional, Negro, Alejandra, additional, and Sangro, Bruno, additional

Published
2023
Full Text
View/download PDF

34. Modeling of Proliferating CD4 and CD8 T‐Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma

Author

Song, Xuyang, primary, Kelley, Robin Kate, additional, Green, Michelle, additional, Standifer, Nathan, additional, Lim, KyoungSoo, additional, Zhou, Diansong, additional, Dunyak, James, additional, Negro, Alejandra, additional, Kurland, John F., additional, Ren, Song, additional, Khan, Anis A., additional, Gibbs, Megan, additional, and Abou‐Alfa, Ghassan K., additional

Published
2023
Full Text
View/download PDF

35. Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma

Author

Spencer, Kristen, primary, Pappas, Leontios, additional, Baiev, Islam, additional, Maurer, Jordan, additional, Bocobo, Andrea Grace, additional, Zhang, Karen, additional, Jain, Apurva, additional, De Armas, Anaemy Danner, additional, Reyes, Stephanie, additional, Le, Tri Minh, additional, Rahma, Osama E, additional, Stanton, Jennifer, additional, DeLeon, Thomas T, additional, Roth, Marc, additional, Peters, Mary Linton B, additional, Zhu, Andrew X, additional, Lennerz, Jochen K, additional, Iafrate, A John, additional, Boyhen, Kylie, additional, VanCott, Christine, additional, Roberts, Lewis R, additional, Lindsey, Stacie, additional, Horick, Nora, additional, Goff, Laura Williams, additional, Mody, Kabir, additional, Borad, Mitesh J, additional, Shroff, Rachna T, additional, Kelley, Robin Kate, additional, Javle, Milind M, additional, and Goyal, Lipika, additional

Published
2023
Full Text
View/download PDF

36. Supplementary Methods, Tables, and Figure from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

Author

Meric-Bernstam, Funda, primary, Bahleda, Rastislav, primary, Hierro, Cinta, primary, Sanson, Marc, primary, Bridgewater, John, primary, Arkenau, Hendrik-Tobias, primary, Tran, Ben, primary, Kelley, Robin Kate, primary, Park, Joon Oh, primary, Javle, Milind, primary, He, Yaohua, primary, Benhadji, Karim A., primary, and Goyal, Lipika, primary

Published
2023
Full Text
View/download PDF

37. Data from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

Author

Meric-Bernstam, Funda, primary, Bahleda, Rastislav, primary, Hierro, Cinta, primary, Sanson, Marc, primary, Bridgewater, John, primary, Arkenau, Hendrik-Tobias, primary, Tran, Ben, primary, Kelley, Robin Kate, primary, Park, Joon Oh, primary, Javle, Milind, primary, He, Yaohua, primary, Benhadji, Karim A., primary, and Goyal, Lipika, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Data DS1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Author

Song, Xuyang, primary, Kelley, Robin Kate, primary, Khan, Anis A., primary, Standifer, Nathan, primary, Zhou, Diansong, primary, Lim, KyoungSoo, primary, Krishna, Rajesh, primary, Liu, Lu, primary, Wang, Kun, primary, McCoon, Patricia, primary, Negro, Alejandra, primary, He, Philip, primary, Gibbs, Megan, primary, Kurland, John F., primary, and Abou-Alfa, Ghassan K., primary

Published
2023
Full Text
View/download PDF

39. Figure S3 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Author

Song, Xuyang, primary, Kelley, Robin Kate, primary, Khan, Anis A., primary, Standifer, Nathan, primary, Zhou, Diansong, primary, Lim, KyoungSoo, primary, Krishna, Rajesh, primary, Liu, Lu, primary, Wang, Kun, primary, McCoon, Patricia, primary, Negro, Alejandra, primary, He, Philip, primary, Gibbs, Megan, primary, Kurland, John F., primary, and Abou-Alfa, Ghassan K., primary

Published
2023
Full Text
View/download PDF

40. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Kelley, Robin Kate, primary, Ueno, Makoto, additional, Yoo, Changhoon, additional, Finn, Richard S, additional, Furuse, Junji, additional, Ren, Zhenggang, additional, Yau, Thomas, additional, Klümpen, Heinz-Josef, additional, Chan, Stephen L, additional, Ozaka, Masato, additional, Verslype, Chris, additional, Bouattour, Mohamed, additional, Park, Joon Oh, additional, Barajas, Olga, additional, Pelzer, Uwe, additional, Valle, Juan W, additional, Yu, Li, additional, Malhotra, Usha, additional, Siegel, Abby B, additional, Edeline, Julien, additional, Vogel, Arndt, additional, Akce, Mehmet, additional, Ales Diaz, Immaculada, additional, Alves, Gustavo, additional, Anand, Sumitra, additional, Arslan, Cagatay, additional, Asselah, Jamil, additional, Assenat, Eric, additional, Aubin, Francine, additional, Bai, Li-Yuan, additional, Bai, Yuxian, additional, Bates, Susan, additional, Begbie, Stephen, additional, Ben-Aharon, Irit, additional, Beri, Nina, additional, Berres, Marie-Luise, additional, Blanc, Jean-Frederic, additional, Borbath, Ivan, additional, Bordonaro, Robert, additional, Brandi, Giovanni, additional, Burgoyne, Adam, additional, Butthongkomvong, Kritiya, additional, Cao, Ke, additional, Carballido, Marcela, additional, Camandaroba, Marcos, additional, Chang, Stephan Lam, additional, Chen, Jen-Shi, additional, Chen, Ming-Huang, additional, Chen, Xiaoming, additional, Cheng, Ashley, additional, Chiu, Tai-Jan, additional, Choi, Hye Jin, additional, Chon, Hong Jae, additional, Collignon, Joelle, additional, Cubillo Gracian, Antonio, additional, Davis, Sarah, additional, de Carvalho, Ricardo Saraiva, additional, de Groot, D.J.A., additional, Demols, Anne, additional, De Vos, Judith, additional, Diab, Maria, additional, Easaw, Jacob, additional, Eatock, Martin, additional, Elias, Rawad, additional, Eskens, Fredericus, additional, Falcone, Alfredo, additional, Fernandez, Plinio, additional, Finn, Richard, additional, Franke, Fabio, additional, Furukawa, Masayuki, additional, Gbolahan, Olumide, additional, Geboes, Karen, additional, Geneser, Keri-Lee, additional, Geng, Zhimin, additional, Geva, Ravit, additional, Gillmore, Roopinder, additional, Goetze, Thorsten, additional, Gou, Hongfeng, additional, Grasselli, Julieta, additional, Gu, Shanzhi, additional, Gumus, Mahmut, additional, Haj Mohammad, Nadia, additional, Hao, Chunyi, additional, Harputluoglu, Hakan, additional, Hatoum, Hassan, additional, Heinemann, Volker, additional, Ho, Wang Kwong, additional, Hsu, Chiun, additional, Hubert, Ayala, additional, Hwang, Juneul, additional, Inanc, Mevlude, additional, Iseas, Soledad, additional, Jeyasingam, Vaishnavi, additional, Jimenez Fonseca, Paula, additional, Joubert, Warren, additional, Juengsamarn, Jitlada, additional, Kaen, Diego, additional, Kanai, Masahi, additional, Kasper-Virchow, Stefan, additional, Kazemi, Ghazaleh, additional, Kelleher, Fergal, additional, Kelley, Robin, additional, Kim, Jin Won, additional, Kim, Jong Gwang, additional, Kinupe Abrahao, Ana Beatriz, additional, Klumpen, Heinz, additional, Kochenderfer, Mark, additional, Kose, Fatih, additional, Lam, Ho Ching, additional, Lee, Choong-kun, additional, Lee, Hyun Woo, additional, Lee, Margaret, additional, Lee, Myung Ah, additional, Lee, Wai Man Sarah, additional, Le Sourd, Samuel, additional, Li, Dongliang, additional, Li, Wei, additional, Liang, Houjie, additional, Liang, Tingbo, additional, Lim, Chun Sen, additional, Lingerfelt, Brian, additional, Lopez, Charles, additional, Low, John, additional, Macarulla Mercade, Teresa, additional, Malka, David, additional, Mao, Yimin, additional, Masi, Gianluca, additional, McCune, Steven, additional, McDermott, Ray, additional, McWhirter, Elaine, additional, Mendez, Guillermo, additional, Milella, Michele, additional, Mizutani, Tomonori, additional, Moniz, Camila, additional, Morales, Luisa, additional, Munoz Martin, Andres Jesús, additional, Nervi, Bruno, additional, Ngamphaiboon, Nuttapong, additional, Oh, Sang Cheul, additional, Oksuzoglu, Berna, additional, Outlaw, Darryl, additional, Ozguroglu, Mustafa, additional, Ozyilkan, Ozgur, additional, Painemeal, Claudio, additional, Pan, Yueyin, additional, Peng, Chuang, additional, Petorin, Caroline, additional, Pezet, Denis, additional, Power, Derek, additional, Qin, Shukui, additional, Roohullah, Aflah, additional, Ryu, Hyewon, additional, Salman, Pamela, additional, Sasidharan, Rita, additional, Satho, Taroh, additional, Schulze, Kornelius, additional, Scott-Brown, Martin, additional, Segovia, Ruben, additional, Seufferlin, Thomas, additional, Siena, Salvatore, additional, Sinapi, Isabelle, additional, Smolenschi, Cristina, additional, Song, Tianqiang, additional, Sookprasert, Aumkhae, additional, Soparattanapaisarn, Nopadol, additional, Starling, Naureen, additional, Stein, Stacey, additional, Stemmer, Salomon, additional, Su, Haichuan, additional, Sugimoto, Rie, additional, Suksombooncharoen, Thatthan, additional, Tam, Vincent, additional, Tan, Ai Lian, additional, Tan, Chih Kiang, additional, Tanasanvimon, Suebpong, additional, Tonini, Giuseppe, additional, Tortora, Giampaolo, additional, Tsuji, Akihito, additional, Uribe, Rodrigo, additional, Venerito, Marino, additional, Verdaguer Mata, Helena, additional, Victorino, Ana Paula, additional, Wade, James, additional, Waldschmidt, Dirk Thomas, additional, Wang, Lu, additional, Wan Isahk, Wan Zamaniah, additional, Wasan, Harpeet, additional, Weschenfelder, Rui, additional, Wong, Chun Yin, additional, Wong, Yoke Fui, additional, Yalcin, Suayib, additional, Yanez Weber, Patricio, additional, Yang, Xuezhong, additional, Yasui, Hisateru, additional, Yazici, Ozan, additional, Yen, Chia-Jui, additional, Ying, Jieer, additional, Yu, Wenchang, additional, and Zhao, Haitao, additional

Published
2023
Full Text
View/download PDF

41. Supp Figure S3 from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma

Author

Kelley, Robin Kate, primary, Meyer, Tim, primary, Rimassa, Lorenza, primary, Merle, Philippe, primary, Park, Joong-Won, primary, Yau, Thomas, primary, Chan, Stephen L., primary, Blanc, Jean-Frederic, primary, Tam, Vincent C., primary, Tran, Albert, primary, Dadduzio, Vincenzo, primary, Markby, David W., primary, Kaldate, Rajesh, primary, Cheng, Ann-Lii, primary, El-Khoueiry, Anthony B., primary, and Abou-Alfa, Ghassan K., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Data from Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma

Author

Kelley, Robin Kate, primary, Meyer, Tim, primary, Rimassa, Lorenza, primary, Merle, Philippe, primary, Park, Joong-Won, primary, Yau, Thomas, primary, Chan, Stephen L., primary, Blanc, Jean-Frederic, primary, Tam, Vincent C., primary, Tran, Albert, primary, Dadduzio, Vincenzo, primary, Markby, David W., primary, Kaldate, Rajesh, primary, Cheng, Ann-Lii, primary, El-Khoueiry, Anthony B., primary, and Abou-Alfa, Ghassan K., primary

Published
2023
Full Text
View/download PDF

43. A phase II study of hypofractionated radiation therapy to augment immune response in patients with metastatic gastrointestinal malignancies progressing on immune therapy (ARM-GI).

Author

Chang, Hewitt, primary, Andemicael, Luchia, additional, Anwar, Moshiur Mekhail, additional, Gordan, John, additional, Johnson, Jamese, additional, Keenan, Bridget P, additional, Kelley, Robin Kate, additional, Ko, Andrew H., additional, Van Loon, Katherine, additional, Venook, Alan P., additional, Fong, Lawrence, additional, Xu, Melody Ju, additional, and Feng, Mary Uan-Sian, additional

Published
2023
Full Text
View/download PDF

44. SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.

Author

Shroff, Rachna T., primary, Guthrie, Katherine A, additional, Scott, Aaron James, additional, Borad, Mitesh J., additional, Goff, Laura Williams, additional, Matin, Khalid, additional, Mahipal, Amit, additional, Kalyan, Aparna, additional, Javle, Milind M., additional, Aghajanian, Carol, additional, Tan, Benjamin R., additional, Cheema, Puneet S., additional, Patel, Anuj K., additional, Iyer, Renuka V., additional, Kelley, Robin Kate, additional, Thumar, Jaykumar Ranchodbhai, additional, El-Khoueiry, Anthony B., additional, Chiorean, E. Gabriela, additional, Hochster, Howard S., additional, and Philip, Philip Agop, additional

Published
2023
Full Text
View/download PDF

45. Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.

Author

Andemicael, Luchia, primary, Chang, Hewitt, additional, Anwar, Moshiur Mekhail, additional, Bauer, Kelly, additional, Gordan, John, additional, Johnson, Jamese, additional, Keenan, Bridget P, additional, Venook, Alan P., additional, Wang, Chia-Ching Jackie, additional, Zhang, Karen, additional, Fong, Lawrence, additional, Kelley, Robin Kate, additional, and Feng, Mary Uan-Sian, additional

Published
2023
Full Text
View/download PDF

47. Impact of viral aetiology in the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

Author

Berres, Marie-Luise, additional, Chan, Stephan L., additional, Kudo, Masatoshi, additional, Sangro, Bruno, additional, Kelley, Robin Kate, additional, Furuse, Junji, additional, Park, Joong-Won, additional, Sunpaweravong, Patrapim, additional, Fasolo, Angelica, additional, Yau, Thomas, additional, Kawaoka, Tomokazu, additional, Cheng, Ann-Li, additional, Azevedo, Sergio, additional, Reig, Maria, additional, Assenat, Eric, additional, Yarchoan, Mark, additional, He, Aiwu R, additional, Makowsky, Mallory, additional, Ran, Di, additional, Negro, Alejandra, additional, and Abou-Alfa, Ghassan, additional

Published
2023
Full Text
View/download PDF

49. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Author

Abou-Alfa, Ghassan K., primary, Lau, George, additional, Kudo, Masatoshi, additional, Chan, Stephen L., additional, Kelley, Robin Kate, additional, Furuse, Junji, additional, Sukeepaisarnjaroen, Wattana, additional, Kang, Yoon-Koo, additional, Van Dao, Tu, additional, De Toni, Enrico N., additional, Rimassa, Lorenza, additional, Breder, Valeriy, additional, Vasilyev, Alexander, additional, Heurgué, Alexandra, additional, Tam, Vincent C., additional, Mody, Kabir, additional, Thungappa, Satheesh Chiradoni, additional, Ostapenko, Yuriy, additional, Yau, Thomas, additional, Azevedo, Sergio, additional, Varela, María, additional, Cheng, Ann-Lii, additional, Qin, Shukui, additional, Galle, Peter R., additional, Ali, Sajid, additional, Marcovitz, Michelle, additional, Makowsky, Mallory, additional, He, Philip, additional, Kurland, John F., additional, Negro, Alejandra, additional, and Sangro, Bruno, additional

Published
2022
Full Text
View/download PDF

50. Abstract 2145: Genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial

Author

Neely, Jaclyn, primary, Yao, Jin, additional, Kudo, Masatoshi, additional, Finn, Richard S., additional, Sangro, Bruno, additional, Melero, Ignacio, additional, El-Khoueiry, Anthony, additional, Tschaika, Marina, additional, Begic, Damir, additional, Sama, Ashwin, additional, Doshi, Parul, additional, Yau, Thomas, additional, and Kelley, Robin Kate, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results